首页>
外国专利>
Paclitaxel-Hyaluronic Acid Conjugate in the Treatment of Non-Muscle Invasive Bladder Cancer
Paclitaxel-Hyaluronic Acid Conjugate in the Treatment of Non-Muscle Invasive Bladder Cancer
展开▼
机译:紫杉醇 - 透明质酸缀合物治疗非肌肉侵袭性膀胱癌
展开▼
页面导航
摘要
著录项
相似文献
摘要
For use in the treatment of non-muscle invasive bladder cancer (NMIBC) by intravesical instillation following a once-weekly dose of 600 mg per week or a twice-weekly dose equivalent to a total of 1,200 mg per week for 12 weeks or 6 consecutive weeks of treatment A pharmaceutical composition consisting essentially of a paclitaxel prodrug in association with a pharmaceutically acceptable diluent/excipient is described. The paclitaxel prodrug used was prepared by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and the chemotherapeutic agent according to the indirect synthesis process between the hyaluronic acid (HA) molecule and the paclitaxel molecule.
展开▼